Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial

Keyphrases

• Randomized Double-blind 100%
• Psoriatic Arthritis 100%
• Risankizumab 100%
• Placebo 50%
• Intolerant 20%
• ACR20 20%
• Conventional Synthetic Disease-modifying Antirheumatic Drugs 20%
• Adverse Events 10%
• Placebo Groups 10%
• Randomized Placebo-controlled Trial 10%
• Trial Registration 10%
• Serious Adverse Events 10%
• Biological Therapy 10%
• Enthesitis 10%
• American College of Rheumatology Criteria 10%
• Treatment Results 10%
• Interleukin-23 (IL-23) 10%
• Serious Infection 10%
• Dactylitis 10%
• Urosepsis 10%
• Minimal Disease Activity 10%
• Nail Psoriasis 10%
• Skin Psoriasis 10%
• Disease Resolution 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Psoriatic Arthritis 100%
• Risankizumab 100%
• Placebo 70%
• Adverse Event 20%
• Disease Modifying Antirheumatic Drug 20%
• Disease Activity 10%
• Physical Disease by Body Function 10%
• Infection 10%
• Interleukin 23 10%
• Dactylitis 10%
• Enthesitis 10%
• Urosepsis 10%
• Nail Psoriasis 10%